Sara Panigone graduated in Medical Biotechnology in 2004 at the University of Milan and then obtained a PhD in Biotechnology Applied to Medical Sciences in collaboration with Stanford University, where she worked as visiting researcher.
She started working in Chiesi Group in 2007 initially in a Medical Affairs role and later becoming Head of Global Competitive Intelligence.
In 2019, she assumed the role of Sustainable Device Transition Leader with focus on the development of Carbon Minimal Inhalers. In this role, she published papers on inhalers carbon footprint and development of inhalers containing new low-global-warming-potential propellants. She also presented as speaker in scientific and public meetings, including an event at the European Parliament.
Since January 2022, she’s been the Chair of the International Pharmaceutical Aerosol Consortium (IPAC) Board of Directors.
